Marisa Frackman

Marisa Frackman is the Chief Financial Officer at Sapience Therapeutics. She is a seasoned financial executive with 18 years of biotechnology capital markets experience.

Most recently, she served as Managing Director at ICR Westwicke within the Healthcare Capital Markets Advisory team. In this capacity, she advised a wide array of private and public clients on strategies related to the preparation and execution of IPOs, follow-ons and pre-IPO financings.

Prior to ICR Westwicke, Ms. Frackman spent 15 years in investment banking. As Director on the Equity Capital Markets team at Wells Fargo Securities, she was responsible for the origination, structuring and execution of equity financing transactions for clients across the healthcare sector. In this capacity, she executed active bookrun transactions ranging in size from $20 million to $5 billion and played a key role in growing the firm’s biotechnology franchise. Ms. Frackman began her Wall Street career as a member of the Healthcare Investment Banking group at Deutsche Bank Securities, where she gained experience in both strategic and financing transactions for public and private companies. During her years as an investment banker, she executed more than 250 equity offerings which raised more than $90 billion in aggregate.

Ms. Frackman graduated cum laude from the McDonough School of Business at Georgetown University with a major in finance and a minor in English.